|
|
|
Price: $9.0100
$-0.21 
-2.278%
|
| Day's High:
| $9.21
| Week Perf:
| -10.88 %
|
| Day's Low: |
$ 8.98 |
30 Day Perf: |
-13.86 % |
| Volume (M): |
143 |
52 Wk High: |
$ 13.79 |
| Volume (M$): |
$ 1,291 |
52 Wk Avg: |
$11.48 |
| Open: |
$9.20 |
52 Wk Low: |
$7.35 |
|
|
| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
- |
| Employees |
425 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
0 |
| Cash Flow (TTM) (Millions $) |
66 |
| Capital Exp. (TTM) (Millions $) |
33 |
Alvotech
Company Address: 9 Luxembourg 1273
Company Phone Number: 422 4500 Stock Exchange / Ticker: NASDAQ ALVO
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Equity Market Information
Published Wed, Jun 11 2025 9:48 PM UTC
The biotechnology landscape is continuously evolving, driven by scientific advancements and the growing demand for affordable therapies. A notable development in this sector is the recent private placement completed by Alvotech (NASDAQ: ALVO, ALVOSDB), a leading biopharmaceutical company known for its focus on biosimilar medicines. This significant financial maneuver, which...
|
| Equity Market Information
Published Wed, Jun 4 2025 4:06 PM UTC
Alvotech, a dedicated biotechnology company specializing in the development of high-quality biosimilars, has announced its intention to engage in a private placement of approximately 7.5 million Swedish Depository Receipts (SDRs) and ordinary shares. This financial maneuver comes at a pivotal moment for the company, as it marks a strategic step in bolstering its resources a...
|
| Announcement
Published Tue, May 27 2025 9:38 AM UTC
As preparations ramp up for Alvotech s Annual General Meeting on June 25, 2025, at the esteemed premises of Arendt & Medernach in Luxembourg, the company stands poised at a critical juncture in its development. This meeting not only marks an essential ritual of corporate governance but also serves as a platform for stakeholders to engage in candid discussions about the compa...
|
| Announcement
Published Fri, May 9 2025 4:29 PM UTC
Alvotech (NASDAQ: ALVO), a prominent global biotech company dedicated to the development and manufacture of biosimilar medicines, is gearing up for its participation in the upcoming BofA Securities Healthcare Conference 2025 in Las Vegas, Nevada, scheduled for May 13-15, 2025. The event serves as a platform for the company to engage with investors, presenting a unique opport...
|
| Equity Market Information
Published Thu, Mar 20 2025 7:58 AM UTC
Alvotech Bolsters Global Biosimilar Leadership through Acquisition of Xbrane s R&D Operations in Sweden In a significant development for the global biosimilars market, Alvotech (NASDAQ: ALVO), a leading biotech firm renowned for its focus on biosimilar medicines, has announced the strategic acquisition of the Research and Development (R&D) operations of Xbrane Biopharma AB, ...
|
| Per Share |
Current |
| Earnings (TTM) |
0 $ |
| Revenues (TTM) |
-
|
| Cash Flow (TTM) |
- |
| Cash |
-
|
| Book Value |
-
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
0 $
|
| Revenues (TTM) |
- |
| Cash Flow (TTM) |
- |
| Cash |
-
|
| Book Value |
- |
| Dividend (TTM) |
0 $ |
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
